Hong Kong expects inquiry into BioNTech packaging defects in a few days
Hong Kong expects the preliminary findings of a study into packaging defects of the COVID-19 vaccine developed by Germany's BioNTech SE as soon as in a few days, the South China Morning hours Post reported on Saturday, citing Secretary for the Civil Service Patrick Nip (bit.ly/3w3c1ZN).
Nip said he had personally requested senior management of China's Fosun Pharma to ship a fresh batch of the vaccines to Hong Kong if there have been safety concerns with the prevailing ones, the SCMP reported. The BioNTech vaccine is distributed in Hong Kong and Macau through a partnership with Fosun Pharma. BioNTech partners with Pfizer Inc in market segments outside greater China.
BioNTech said on March 24 it had made a decision to pause further vaccination with the batch before investigation is complete as a good precautionary measure and that zero other batches shipped to other regions are actually affected by this investigation. People are expected to get their booster dose before mid-April, Nip explained on a radio show, in line with the SCMP report. "
We gives priority to those that need the second dose whenever we assign the new period slots and venues once the vaccinations with BioNTech can resume," the statement added.Hong Kong and Macau halted the utilization of a COVID-19 vaccine produced by BioNTech on Wednesday, citing defective packaging, in a approach that triggered scenes of confusion on inoculation centers over the city.
